• +1-646-491-9876
    • +91-20-67278686

    Search

    House Dust Mite Allergy Pipeline Review H2 2017

    House Dust Mite Allergy Pipeline Review H2 2017

    • Report Code ID: RW0001884148
    • Category Pharmaceuticals
    • No. of Pages 43
    • Publication Month Jul-17
    • Publisher Name Global Markets Direct
    House Dust Mite Allergy - Pipeline Review, H2 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide House Dust Mite Allergy - Pipeline Review, H2 2017, provides an overview of the House Dust Mite Allergy (Immunology) pipeline landscape.

    House dust mite allergy is an allergic reaction to tiny bugs that commonly live in house dust. Symptoms include frequent sneezing, a runny, stuffy, itchy nose and irritated eyes. Asthma and eczema can also be triggered by a dust mite allergy. Symptoms often worsen when the individual comes in close proximity to disturbed dust. The predisposing factors include family history and age. Treatment includes antihistamines, decongestants and corticosteroids.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide House Dust Mite Allergy - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for House Dust Mite Allergy (Immunology) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The House Dust Mite Allergy (Immunology) pipeline guide also reviews of key players involved in therapeutic development for House Dust Mite Allergy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, IND/CTA Filed, Preclinical and Discovery stages are 2, 1, 1, 2 and 1 respectively.

    House Dust Mite Allergy (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of House Dust Mite Allergy (Immunology) .
    - The pipeline guide reviews pipeline therapeutics for House Dust Mite Allergy (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in House Dust Mite Allergy (Immunology) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates House Dust Mite Allergy (Immunology) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for House Dust Mite Allergy (Immunology)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for House Dust Mite Allergy (Immunology) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding House Dust Mite Allergy (Immunology) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    House Dust Mite Allergy - Overview
    House Dust Mite Allergy - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Products under Development by Companies
    House Dust Mite Allergy - Therapeutics Assessment
    Assessment by Route of Administration
    Assessment by Molecule Type
    House Dust Mite Allergy - Companies Involved in Therapeutics Development
    ALK-Abello A/S
    Allergy Therapeutics Plc
    Anergis SA
    Biomay AG
    Stallergenes Greer plc
    Zhejiang I-Biological Technology Co Ltd
    House Dust Mite Allergy - Drug Profiles
    Acarovac Quattro - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AllerDM - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BM-35 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    house dust mite (Dermatophagoides farinae) allergen extract - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PL-103 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    standardized mite (Dermatophagoides farinae + Dermatophagoides pteronyssinus) allergen extract - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    standardized mite (Dermatophagoides pteronyssinus + Dermatophagoides farinae) allergen vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    House Dust Mite Allergy - Dormant Projects
    House Dust Mite Allergy - Discontinued Products
    House Dust Mite Allergy - Product Development Milestones
    Featured News & Press Releases
    May 04, 2017: ALK's HDM SLIT-tablet, ACARIZAX, approved in Canada
    Apr 16, 2017: ACARIZAX approved in Europe for use in adolescent patients with house dust mite-induced allergic rhinitis
    Mar 01, 2017: FDA approves Odactra for house dust mite allergies
    Feb 14, 2017: Allergy Therapeutics Announces Novel House Dust Mite Allergy Vaccine Gains Clinical Trial Application Approval
    Jan 27, 2017: Stallergenes Greer Announces Positive Top-Line Results Of Phase 3 Study For Pediatric House Dust Mite-Induced Allergic Rhinitis
    Apr 27, 2016: Journal of the American Medical Association publishes Phase III data from allergic asthma trial with ALK house dust mite SLIT-tablet, ACARIZAX
    Apr 13, 2016: License application for investigational house dust mite SLIT-tablet accepted for review by FDA
    Apr 12, 2016: Merck Announces FDA Acceptance of Biologics License Application for Investigational House Dust Mite Sublingual Allergy Immunotherapy Tablet
    Apr 05, 2016: Stallergenes Greer Announces The Approval Of Actair In Australia
    Jan 27, 2016: Marketing authorisation for ACARIZAX issued in France
    Dec 09, 2015: New product (ACARIZAX) for treatment of house dust mite allergic rhinitis and asthma obtains reimbursement in Denmark
    Nov 26, 2015: New medicine for house dust mite allergic rhinitis now available in Japan
    Nov 19, 2015: Desensitization Therapy Actair House Dust Mite Sublingual Tablets Launched in Japan
    Sep 28, 2015: ALK's partner, Torii, obtains approval for the house dust mite SLIT-tablet in Japan
    Jun 09, 2015: ALK's partner, MSD, publishes Phase II data on house dust mite SLIT-tablet in leading allergy journal
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for House Dust Mite Allergy, H2 2017
    Number of Products under Development by Companies, H2 2017
    Products under Development by Companies, H2 2017
    Number of Products by Stage and Route of Administration, H2 2017
    Number of Products by Stage and Molecule Type, H2 2017
    House Dust Mite Allergy - Pipeline by ALK-Abello A/S, H2 2017
    House Dust Mite Allergy - Pipeline by Allergy Therapeutics Plc, H2 2017
    House Dust Mite Allergy - Pipeline by Anergis SA, H2 2017
    House Dust Mite Allergy - Pipeline by Biomay AG, H2 2017
    House Dust Mite Allergy - Pipeline by Stallergenes Greer plc, H2 2017
    House Dust Mite Allergy - Pipeline by Zhejiang I-Biological Technology Co Ltd, H2 2017
    House Dust Mite Allergy - Dormant Projects, H2 2017
    House Dust Mite Allergy - Discontinued Products, H2 2017

    List of Figures

    Number of Products under Development for House Dust Mite Allergy, H2 2017
    Number of Products under Development by Companies, H2 2017
    Number of Products by Routes of Administration, H2 2017
    Number of Products by Stage and Routes of Administration, H2 2017
    Number of Products by Molecule Types, H2 2017
    Number of Products by Stage and Molecule Types, H2 2017
    ALK-Abello A/S
    Allergy Therapeutics Plc
    Anergis SA
    Biomay AG
    Stallergenes Greer plc
    Zhejiang I-Biological Technology Co Ltd

    Request for Sample

    Report Url https://www.reportsweb.com//house-dust-mite-allergy-pipeline-review-h2-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//house-dust-mite-allergy-pipeline-review-h2-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//house-dust-mite-allergy-pipeline-review-h2-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments